{"denoms":[{"counts":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"184"}],"units":"Participants"}],"groups":[{"description":"3 cycles of standard of care (SOC) salvage therapy (rituximab, dexamethasone, cytarabine and cisplatin \\[R-DHAP\\], rituximab, ifosfamide, carboplatin and etoposide \\[R-ICE\\], rituximab, gemcitabine, dexamethasone, and cisplatin \\[R-GDP\\]) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks","id":"BG000","title":"Standard of Care Arm"},{"description":"\\[Lymphodepleting chemotherapy (LDC)\\] Fludarabine IV (30 mg/m\\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)","id":"BG001","title":"Liso-cel Arm"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.94","value":"54.2"},{"groupId":"BG001","spread":"12.61","value":"58.3"},{"groupId":"BG002","spread":"13.41","value":"56.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"79"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"105"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"127"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"51"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"18"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"109"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"47"}]}],"title":"Not Collected or Reported"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}